Hinda Boutrid, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Boutrid’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Drugs they prescribed that Part D paid
$2,436,677
Pharmacies billed $2,436,677 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 16% of their Part D prescriptions (194 of 1,215) in 2024. A higher opioid share than 9 in 10 peers; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 25% of their opioid prescriptions.
1,030 generic and fewer than 11 brand-name prescriptions · $2,436,677 in drug cost · 11 antibiotic prescriptions · 18 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ibrance | 45 | $692,923 | $15,398 |
| Lynparza | 22 | $369,299 | $16,786 |
| Lenalidomide | 27 | $346,222 | $12,823 |
| Alecensa | 15 | $302,222 | $20,148 |
| Sprycel | 11 | $60,616 | $5,511 |
See all 27 drugs
| Ibrance | 45 | $692,923 | $15,398 |
| Lynparza | 22 | $369,299 | $16,786 |
| Lenalidomide | 27 | $346,222 | $12,823 |
| Alecensa | 15 | $302,222 | $20,148 |
| Sprycel | 11 | $60,616 | $5,511 |
| Oxycontin | 28 | $16,494 | $589 |
| Abiraterone Acetate | 27 | $7,329 | $271 |
| Anastrozole | 134 | $3,775 | $28 |
| Hydrocodone-Acetaminophen | 71 | $2,105 | $30 |
| Oxycodone-Acetaminophen | 22 | $1,130 | $51 |
| Oxycodone | 35 | $961 | $27 |
| Dexamethasone | 51 | $914 | $18 |
| Lorazepam | 46 | $839 | $18 |
| Diphenoxylate-Atropine | 32 | $810 | $25 |
| Morphine Sulfate Er | 12 | $747 | $62 |
| Letrozole | 34 | $692 | $20 |
| Tamoxifen Citrate | 26 | $692 | $27 |
| Ondansetron | 69 | $680 | $10 |
| Famotidine | 54 | $628 | $12 |
| Prednisone | 63 | $558 | $9 |
| Levothyroxine | 26 | $475 | $18 |
| Lactulose | 14 | $334 | $24 |
| Gabapentin | 15 | $290 | $19 |
| Ondansetron Odt | 13 | $274 | $21 |
| Lidocaine-Prilocaine | 13 | $236 | $18 |
| Alprazolam | 15 | $144 | $10 |
| Olanzapine | 20 | $142 | $7 |
Year by year
| 2024 | 1,215 | 189 | 16% (194) | None | $2,436,677 |
| 2023 | 1,186 | 206 | 14% (163) | 18% | $2,559,429 |
| 2022 | 970 | 164 | 15% (145) | None | $1,741,327 |
| 2021 | 775 | 158 | 13% (100) | 15% | $967,059 |
| 2020 | 846 | 137 | 21% (179) | 16% | $805,219 |
| 2019 | 208 | 65 | 13% (26) | 17% | $124,371 |
| 2018 | 53 | 26 | None | None | $3,331 |
| 2017 | 25 | 15 | None | None | $3,405 |
| 2016 | 137 | 23 | None | 15% | $12,259 |
| 2015 | 273 | 38 | None | 11% | $19,878 |
| 2014 | 184 | 41 | None | 21% | $15,433 |
| 2013 | 119 | 28 | None | 20% | $8,151 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 31 drugs
| Ibrance | 60 | $840,779 | $14,013 |
| Alecensa | 15 | $285,301 | $19,020 |
| Lenalidomide | 23 | $273,482 | $11,891 |
| Lynparza | 16 | $258,291 | $16,143 |
| Sprycel | 18 | $184,337 | $10,241 |
| Oxycontin | 28 | $13,908 | $497 |
| Nivestym | 12 | $8,986 | $749 |
| Abiraterone Acetate | 34 | $8,143 | $240 |
| Anastrozole | 113 | $2,962 | $26 |
| Fentanyl | 15 | $1,928 | $129 |
| Dexamethasone | 54 | $1,395 | $26 |
| Hydrocodone-Acetaminophen | 46 | $1,105 | $24 |
| Tamoxifen Citrate | 27 | $846 | $31 |
| Diphenoxylate-Atropine | 29 | $701 | $24 |
| Oxycodone-Acetaminophen | 18 | $692 | $38 |
| Prednisone | 78 | $683 | $9 |
| Letrozole | 35 | $639 | $18 |
| Famotidine | 39 | $637 | $16 |
| Lidocaine-Prilocaine | 25 | $596 | $24 |
| Oxycodone | 31 | $571 | $18 |
| Gabapentin | 23 | $533 | $23 |
| Ondansetron | 47 | $496 | $11 |
| Prochlorperazine Maleate | 20 | $410 | $20 |
| Lactulose | 18 | $358 | $20 |
| Ondansetron Odt | 15 | $300 | $20 |
| Lorazepam | 28 | $256 | $9 |
| Potassium Chloride | 14 | $248 | $18 |
| Levothyroxine | 12 | $238 | $20 |
| Tizanidine | 11 | $207 | $19 |
| Promethazine | 12 | $135 | $11 |
| Alprazolam | 12 | $120 | $10 |
2022: 21 drugs
| Ibrance | 58 | $786,807 | $13,566 |
| Lynparza | 12 | $182,937 | $15,245 |
| Abiraterone Acetate | 19 | $3,402 | $179 |
| Anastrozole | 100 | $2,444 | $24 |
| Dexamethasone | 54 | $1,989 | $37 |
| Fentanyl | 13 | $1,869 | $144 |
| Hydrocodone-Acetaminophen | 64 | $1,552 | $24 |
| Oxycodone-Acetaminophen | 37 | $915 | $25 |
| Exemestane | 11 | $880 | $80 |
| Tamoxifen Citrate | 14 | $738 | $53 |
| Ondansetron | 64 | $647 | $10 |
| Diphenoxylate-Atropine | 22 | $646 | $29 |
| Imatinib Mesylate | 11 | $598 | $54 |
| Letrozole | 26 | $552 | $21 |
| Prochlorperazine Maleate | 16 | $539 | $34 |
| Gabapentin | 22 | $530 | $24 |
| Famotidine | 35 | $415 | $12 |
| Lidocaine-Prilocaine | 22 | $377 | $17 |
| Prednisone | 40 | $342 | $9 |
| Lorazepam | 22 | $211 | $10 |
| Omeprazole | 11 | $165 | $15 |
2021: 21 drugs
| Ibrance | 30 | $378,318 | $12,611 |
| Lynparza | 12 | $178,208 | $14,851 |
| Zarxio | 17 | $12,646 | $744 |
| Anastrozole | 86 | $2,111 | $25 |
| Dexamethasone | 47 | $1,858 | $40 |
| Prochlorperazine Maleate | 28 | $1,109 | $40 |
| Hydrocodone-Acetaminophen | 38 | $1,055 | $28 |
| Tamoxifen Citrate | 18 | $979 | $54 |
| Oxycodone-Acetaminophen | 32 | $756 | $24 |
| Ondansetron | 49 | $558 | $11 |
| Gabapentin | 18 | $434 | $24 |
| Letrozole | 16 | $375 | $23 |
| Lidocaine-Prilocaine | 13 | $373 | $29 |
| Prednisone | 37 | $346 | $9 |
| Levothyroxine | 15 | $292 | $19 |
| Diphenoxylate-Atropine | 11 | $244 | $22 |
| Famotidine | 21 | $232 | $11 |
| Oxycodone | 11 | $220 | $20 |
| Lorazepam | 20 | $208 | $10 |
| Omeprazole | 12 | $197 | $16 |
| Olanzapine | 19 | $138 | $7 |
2020: 23 drugs
| Revlimid | 15 | $261,246 | $17,416 |
| Ibrance | 14 | $201,848 | $14,418 |
| Lynparza | 11 | $161,723 | $14,702 |
| Zarxio | 30 | $58,448 | $1,948 |
| Dexamethasone | 75 | $4,210 | $56 |
| Fentanyl | 20 | $2,577 | $129 |
| Hydrocodone-Acetaminophen | 73 | $2,504 | $34 |
| Anastrozole | 49 | $1,204 | $25 |
| Famotidine | 25 | $1,070 | $43 |
| Prochlorperazine Maleate | 29 | $925 | $32 |
| Ondansetron | 58 | $641 | $11 |
| Morphine Sulfate Er | 32 | $595 | $19 |
| Tamoxifen Citrate | 11 | $493 | $45 |
| Oxycodone-Acetaminophen | 18 | $362 | $20 |
| Prednisone | 33 | $335 | $10 |
| Tramadol | 20 | $277 | $14 |
| Lidocaine Hcl Viscous | 14 | $257 | $18 |
| Letrozole | 11 | $221 | $20 |
| Lorazepam | 26 | $208 | $8 |
| Alprazolam | 16 | $191 | $12 |
| Omeprazole | 11 | $152 | $14 |
| Trazodone | 16 | $131 | $8 |
| Ropinirole | 11 | $131 | $12 |
2019: 5 drugs
| Dexamethasone | 17 | $760 | $45 |
| Anastrozole | 13 | $264 | $20 |
| Letrozole | 17 | $130 | $8 |
| Ondansetron | 11 | $96 | $9 |
| Lorazepam | 12 | $74 | $6 |
2016: 2 drugs
| Levothyroxine | 18 | $302 | $17 |
| Amlodipine Besylate | 19 | $118 | $6 |
2015: 8 drugs
| Levothyroxine | 23 | $436 | $19 |
| Metoprolol | 21 | $369 | $18 |
| Desogestrel-Ethinyl Estradiol | 12 | $201 | $17 |
| Atorvastatin | 16 | $146 | $9 |
| Amlodipine Besylate | 18 | $98 | $5 |
| Clopidogrel | 12 | $78 | $7 |
| Lisinopril | 19 | $74 | $4 |
| Metoprolol | 14 | $68 | $5 |
2014: 2 drugs
| Duloxetine | 11 | $3,633 | $330 |
| Levothyroxine | 21 | $328 | $16 |
2013: 1 drug
| Clopidogrel | 19 | $1,261 | $66 |
Money from drug and device companies
$18 in 2025
A payment is not proof that care is biased.
| Daiichi Sankyo | Enhertu | $18 | 1 payment
|
See the published payment
| Daiichi Sankyo | Meals · 2025-10-16 | Enhertu | $18 |
Professional record
- NPI
- 1457796070
- Trained
- University of South Florida College of Medicine, 2013
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 2589 Samaritan Dr Bay, San Jose, CA, 95124
- NPI first listed
- 2013-05-09
- NPI last updated
- 2025-03-17
- NPI record certified
- 2025-03-17
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.